Anadys reiterated at strong buy by JMP

JMP Securities analyst Michelle Lange reiterated Anadys Pharmaceuticals, Inc. at strong buy. The company has a partnership with Novartis for ANA975 for hepatitis C and is also licensing Human Genome Sciences' Albuferon. JMP sees Anadys as an exciting investment opportunity in small-cap biotechnology. Shares of the San Diego, Calif.-based biopharmaceutical company were down $0.58, or 5.74%, at $9.52 on volume of 644,463 shares versus the three-month running average of 294,720 shares. (Nasdaq: ANDS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.